Teva Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARMS INC
TEVA PHARMS INC has fifteen approved drugs.
There is one US patent protecting TEVA PHARMS INC drugs. There are three tentative approvals on TEVA PHARMS INC drugs.
There are two patent family members on TEVA PHARMS INC drugs in two countries and one hundred and twenty supplementary protection certificates in nineteen countries.
Summary for Teva Pharms Inc
| International Patents: | 2 |
| US Patents: | 1 |
| Tradenames: | 15 |
| Ingredients: | 15 |
| NDAs: | 15 |
Drugs and US Patents for Teva Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Inc | THEOPHYLLINE | theophylline | TABLET, EXTENDED RELEASE;ORAL | 216961-002 | Oct 12, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | PRUCALOPRIDE SUCCINATE | prucalopride succinate | TABLET;ORAL | 219071-002 | Feb 5, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | TIOPRONIN | tiopronin | TABLET, DELAYED RELEASE;ORAL | 216456-002 | Jul 22, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | PACLITAXEL | paclitaxel | POWDER;INTRAVENOUS | 216338-001 | May 11, 2023 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | NILOTINIB HYDROCHLORIDE | nilotinib hydrochloride | CAPSULE;ORAL | 219134-001 | Jun 26, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | AMLODIPINE BESYLATE | amlodipine besylate | TABLET;ORAL | 219686-003 | Jan 22, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-004 | Nov 29, 2023 | RX | Yes | Yes | 11,072,586 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Teva Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3692021 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2019071111 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1294378 | 10C0034 | France | ⤷ Start Trial | PRODUCT NAME: ELTROMBOPAG EVENTUELLEMENT SOUS LA FORME D'UN SEL OU D'UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE (INCLUANT UN HYDRATE); REGISTRATION NO/DATE: EU/1/10/612/001 20100315 |
| 2101777 | 93081 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125 |
| 0247633 | 97C0118 | France | ⤷ Start Trial | PRODUCT NAME: ATORVASTATINE CALCIQUE TRIHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 21960 DU 19970321; REGISTRATION NO/DATE AT EEC: PL 00018/0240 DU 19961107 |
| 2059246 | CA 2024 00050 | Denmark | ⤷ Start Trial | PRODUCT NAME: KOMBINATION AF (A) MACITENTAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG (B) TADALAFIL ELLER ET FAR-MACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/24/1859 20240930 |
| 2330892 | 63/2016 | Austria | ⤷ Start Trial | PRODUCT NAME: GLYCEROLPHENYLBUTYRAT; REGISTRATION NO/DATE: EU/1/15/1062 (MITTEILUNG) 20151201 |
| 2059246 | LUC00371 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF (A) MACITENTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) TADALAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/24/1859 20240930 |
| 0720599 | CR 2014 00050 | Denmark | ⤷ Start Trial | PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
